Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PCSA Processa Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: PCSA
Price (delayed)
$0.1948
Market cap
$2.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.08
Enterprise value
-$532,340
Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a
Highlights
PCSA's debt has dropped by 65% year-on-year and by 32% since the previous quarter
The EPS has soared by 51% YoY and by 20% from the previous quarter
Processa Pharmaceuticals's quick ratio has surged by 190% QoQ but it has shrunk by 74% YoY
Processa Pharmaceuticals's equity has surged by 108% QoQ but it has shrunk by 60% YoY
PCSA's net income is down by 22% YoY
Key stats
What are the main financial stats of PCSA
Market
Valuations
Earnings
Shares outstanding
11.88M
Market cap
$2.32M
Enterprise value
-$532,340
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$12M
Net income
-$11.96M
EBIT
-$11.96M
EBITDA
-$11.87M
Free cash flow
-$11.93M
Per share
Balance sheet
Liquidity
EPS
-$3.08
EPS diluted
-$3.08
Free cash flow per share
-$1.25
Book value per share
$0.67
Revenue per share
$0
TBVPS
$0.5
Total assets
$4.81M
Total liabilities
$1.28M
Debt
$49,659
Equity
$3.53M
Working capital
$2.47M
Debt to equity
0.01
Current ratio
2.93
Quick ratio
2.26
Net debt/EBITDA
0.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-232.4%
Return on equity
-319.6%
Return on invested capital
-1,718.5%
Return on capital employed
-339.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCSA stock price
How has the Processa Pharmaceuticals stock price performed over time
Intraday
3.34%
1 week
-18.22%
1 month
-32.43%
1 year
-89.24%
YTD
-77.96%
QTD
-4.98%
Financial performance
How have Processa Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12M
Net income
-$11.96M
Gross margin
N/A
Net margin
N/A
PCSA's net income is down by 22% YoY
Processa Pharmaceuticals's operating income has decreased by 20% YoY
Price vs fundamentals
How does PCSA's price correlate with its fundamentals
Growth
What is Processa Pharmaceuticals's growth rate over time
Valuation
What is Processa Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 51% YoY and by 20% from the previous quarter
Processa Pharmaceuticals's equity has surged by 108% QoQ but it has shrunk by 60% YoY
PCSA's P/B is 90% below its 5-year quarterly average of 2.9 and 74% below its last 4 quarters average of 1.1
Efficiency
How efficient is Processa Pharmaceuticals business performance
Processa Pharmaceuticals's return on equity has shrunk by 146% YoY and by 37% QoQ
The ROA has plunged by 101% YoY and by 26% from the previous quarter
Processa Pharmaceuticals's return on invested capital has increased by 18% QoQ and by 12% YoY
Dividends
What is PCSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCSA.
Financial health
How did Processa Pharmaceuticals financials performed over time
Processa Pharmaceuticals's quick ratio has surged by 190% QoQ but it has shrunk by 74% YoY
The current ratio has surged by 140% since the previous quarter but it has dropped by 70% year-on-year
PCSA's debt is 99% smaller than its equity
Processa Pharmaceuticals's equity has surged by 108% QoQ but it has shrunk by 60% YoY
Processa Pharmaceuticals's debt to equity has plunged by 75% from the previous quarter and by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.